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Synaesthesia is a neurological phenomenon affectingperception,where trigger-
ing stimuli (e.g. letters and numbers) elicit unusual secondary sensory
experiences (e.g. colours). Family-based studiespoint to a role for genetic factors
in thedevelopmentof this trait.However, the contributionsof commongenomic
variation to synaesthesia have not yet been investigated. Here, we present the
SynGenes cohort, the largest genotyped collection of unrelated peoplewith gra-
pheme–colour synaesthesia (n = 723). Synaesthesia has been associated with a
range of other neuropsychological traits, including enhanced memory and
mental imagery, aswell as greater sensory sensitivity.Motivated by the prior lit-
eratureonputative trait overlaps,we investigatedpolygenic scoresderived from
published genome-wide scans of schizophrenia and autism spectrum disorder
(ASD), comparing our SynGenes cohort to 2181 non-synaesthetic controls. We
found a very slight association between schizophrenia polygenic scores and
synaesthesia (Nagelkerke’s R2 = 0.0047, empirical p = 0.0027) and no signifi-
cant association for scores related to ASD (Nagelkerke’s R2 = 0.00092,
empirical p = 0.54) or body mass index (R2 = 0.00058, empirical p = 0.60),
included as a negative control. As sample sizes for studying common genomic
variation continue to increase, genetic investigations of the kind reported here
may yield novel insights into the shared biology between synaesthesia and
other traits, to complement findings fromneuropsychologyandbrain imaging.
This article is part of a discussion meeting issue ‘Bridging senses: novel
insights from synaesthesia’.1. Introduction
Synaesthesia is a neurological phenomenon at the edge of natural variation
in sensory perception. Individuals with synaesthesia (up to approx. 4% of the
population) have unusual secondary sensory experiences when presented
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2with triggering stimuli, typically against a background of
normal neural development. A diverse range of such experi-
ences have been documented; for example, some people with
synaesthesia visualize the days of the week or sequences of
numbers having ordered locations in the space around
them (sequence–space synaesthesia) while for others vivid
taste perceptions are elicited by words (lexical–gustatory
synaesthesia) [1–3]. Grapheme–colour synaesthesia is a rela-
tively common form, with an estimated prevalence of 1.4%
[1]. In this type of synaesthesia, which has been widely
studied over the past 20 years, letters and numbers trigger
the consistent perception of specific colours [4].
Evidence from a range of sources suggests that synaesthesia
is influenced by genetic factors. The precise nature of these
factors is poorly understood, but it is thought that severalmech-
anisms are involved, ranging from rare DNA variants with
large effects (more akin to monogenic inheritance) to combined
actions of common polymorphisms, each with only a small
effect on the trait. Investigations of families wheremultiple rela-
tives are synaesthetic indicate that, even where rare variation
could be responsible, there is substantial genetic heterogeneity,
meaning that distinct genetic loci may be involved in different
families [5–9]. Against this background, we previously perfor-
med a whole-exome sequencing study and found enrichment
of rare variants in genes associated with axonogenesis in
three families with sound–colour synaesthesia [9]. These results
supported a long-standing hypothesis that synaesthesia may
be caused in part by altered or hyperconnectivity between
brain regions processing the inducing and concurrent sensory
stimuli [10,11].
While studies of familial synaesthesia are beginning to show
promise for pinpointing contributions of rare gene variants, a
large proportion of synaesthetes are unaware of other relatives
with similar experiences. Indeed, virtually nothing is known at
present about the potential role of common genetic variation
in synaesthesia. We sought to address this major gap in the
literature. Since investigations of contributions of common
polymorphisms require large sample sizes, in 2013, we initia-
ted a new effort (SynGenes) to systematically recruit and
genotype unrelated individuals with objectively verified gra-
pheme–colour synaesthesia. Genome-wide association studies
(GWAS) are often used as a tool for assessing the contributions
of common genetic variants to a quantitative or binary trait.
A typical GWAS involves determining the genotypes of
hundreds of thousands of single nucleotide polymorphisms
(SNPs) at different positions through a person’s genome and
then systematically testing each SNP to see if there is an associ-
ation between the status of the allele and the trait of interest, in
the cohort as a whole. Given the small effect sizes of individual
common variants, and the multiple-testing burden involved, a
GWAS becomes informativewhen the sample size of the cohort
reaches several thousand individuals or cases. Two decades of
human population genetics research has shown that, as well as
being underpowered, a GWAS performed on smaller sample
sizes can yield spurious results that fail to replicate in larger
cohorts [12].
It is still possible to investigate the genetic architecture of a
trait when sample sizes are too small for a full-scale GWAS,
through more recently developed methods that use aggregated
genotype information from multiple loci across the genome
to examine how two traits are related at a genetic level. Specifi-
cally, alleles associated with increased risk for a binary trait (or
associated with increases in a quantitative trait, like height)can be aggregated into a polygenic risk score (PGS) to assess
genetic association with other phenotypes [13,14]. A PGS
weights the number of independent ‘increaser’ alleles that an
individual carries at different SNPs in their genome with the
respective effect sizes, as measured in an independent GWAS
with sufficient power. This aggregation of information across
the multiple markers yields a score that reflects the individual’s
net balance of alleles that increase or decrease risk for the binary
trait, or that increase/decrease scores on a quantitative trait (as
in the height example). A recent study on the application of
schizophrenia PGS across populations found significant vari-
ation between groups with differences in ancestry, leading to
best practice recommendations that a PGS derived from the
GWAS of one population (most commonly Europeans) should
only be applied to participants from that same population
[14,15]. Despite this limitation, the method is increasingly
being used to link quantitative measurements of brain-related
traits (e.g. executive functioning, neuroticism) in the normal
population togenetic risk fordisorders [16]. Thisprovides afeas-
ibleway to study the genetic relationships between one trait for
which there are large-scale GWAS data available and another
trait that is measured in a cohort of more limited size. For the
former, this is usually a trait that has been the focus of a meta-
analytic effort across multiple cohorts in a consortium, such as
the Psychiatric Genomics Consortium (PGC) [17].
With these limitations in mind, we sought to understand
whether neuropsychological traits that have been previously
linked to synaesthesia at a phenotypic level have any deeper,
genetic relationships. Beyond the synaesthetic experiences
themselves, there is considerable literature on other ways
that synaesthetes differ from non-synaesthetes. These include
cognitive traits like improved memory performance in
synaesthetes, and perceptual traits like increased sensory sensi-
tivity and mental imagery, and as well as greater positive
schizotypy as measured through self-reported unusual percep-
tual experiences [18,19]. There is also an increased prevalence of
synaesthesia among individualswith autism spectrumdisorder
(ASD) [20–22].
When selecting traits for inclusion in the current study, we
were limited to traits with relevant and sufficiently powered
GWAS. While schizophrenia and ASD are complex at both
the phenotypic and genotypic levels, they each include an
element of unusual perceptual differences that may show over-
lapping genetic architecture with synaesthesia in neurotypical
individuals. Such a shared genetic component could be obser-
vable as synaesthetes having higher PGSs for either trait.
Although schizotypy has not been the subject of a GWAS,
one study found that individuals with a higher PGS for schizo-
phrenia (derived fromGWAS sample sizes that are greater than
30 000) also had higher levels of positive and negative schizo-
typy [23]. GWAS efforts in ASD are just beginning to bear
fruit, with a recent meta-analysis of 18 381 cases identifying
five genome-wide significant loci [24].
The current study presents the first set of results from the
SynGenes cohort, the largest collection of genotyped individ-
uals with validated grapheme–colour synaesthesia, involving
genetic analyses of over 700 unrelated people. We used PGS
analyses to assess whether an individual’s aggregate genetic
risk for schizophrenia or ASD influences the likelihood that
they experience synaesthesia. To confirm that our case–control
design was free from confounding differences in genetic ances-
try, we also looked for differences in polygenic scores for body
mass index (BMI), using this heritable trait as a negative
royalsocietypublishing.org/journal/rs
3control. We found that PGSs for schizophrenia are likely to
explain a very small amount (less than 1%) of the variance in
synaesthesia status, an effect similar in size to the relationship
between schizophrenia PGS and creativity, reported in a prior
study [25]. We did not observe any relationships between
PGSs for ASD or BMI and synaesthesia. Our results suggest
that PGSs for schizophrenia do not have a meaningful impact
on whether a person experiences synaesthesia, while at the
same time identifying a small piece of shared biology, perhaps
related to unusual perceptual experiences, that may tie this
intriguing sensory phenomenon into the fabric of modern
psychiatric genetics. tb
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(a) Participant recruitment
Synaesthete participants were recruited at the Max Planck Institute
for Psycholinguistics (MPI) throughmultiple routes. These included
social media (e.g. Twitter, posts in synaesthesia-related Facebook
groups, a Reddit ‘Ask Me Anything’ event in August 2016),
flyers posted at Radboud University, advertising to the Russian
synaesthesiacommunitydatabase, and recontacting consenting indi-
viduals who had previously participated in synaesthesia research
through theGrootNationaalOnderzoek (in English, ‘LargeNational
Study’, http://gno.mpi.nl/tests) [26], the University of Amsterdam,
or the University of Sussex. Those recruited to the genetics study
directly at theUniversity of Edinburghwere contacted through simi-
lar methods, including online advertisements, student forms and
mailing lists, and recontacting previous participants.
Participants initially recruited by the MPI were asked to read a
participant information sheet and provide their informed consent
prior to completing initial surveys and synaesthesia testing.
During the genetic phase of the study, participants were again pro-
vided with the information sheet as well as informed consent
forms. Participants aged between 12 and 18 years were additionally
asked for parent or guardian consent, and the consent formsused for
participants aged between 4 and 12 years asked the parent or guar-
dian for consent on behalf of the child. Ethical approval for the study
was granted by the Ethische Commissie Gedragswetenschappelijk
Onderzoek (Ethics Committee, Faculty of Social Sciences) at Rad-
boud University (application number ECG2013-2504-105).
Participants from the above sources are collectively referred to as
the ‘SynGenes’ cohort.
Both synaesthetes and controls were recruited from the Scottish
FamilyHealthStudy, acohortof over 20 000 individualswithgenetic
and health data collected as part of Generation Scotland [27].
The advertisement for the study included a potential reward of
£100 via a prize draw. All participants provided written informed
consent, and ethical approval for the Generation Scotland project
was granted by the Tayside Committee on Medical Research
Ethics, on behalf of the National Health Service (reference number:
05/S1401/89). The recruitment and data collection process for
Generation Scotland has been described in detail elsewhere [27–29].
Additional non-synaesthetic and population controls were
included from the Nijmegen ‘Brain Imaging Genetics’ cohort
(BIG), a Dutch population-based sample of healthy volunteers that
has been described in detail in several previous studies [30–32].
The BIG study was approved by the regional ethics committee,
and all participants provided written informed consent.(b) Questionnaires and synaesthesia consistency testing
Participants directly recruited by theMax Planck Institutewere able
to join the study through three routes:TheSynesthesia Battery (hosted
by Baylor College of Medicine until 2017, later by the University ofSussex); a web-based survey hosted by the MPI (available at www.
mpi.nl/synaesthesia); or the SynQuiz app (available on iOS and
Android) [33,34]. Each included a survey of synaesthesia types,
including an open field for other forms not listed, basic demo-
graphics (age, gender) and questions about whether the
participant experienced any potentially relevant neurological con-
ditions that might mimic the symptoms of synaesthesia (e.g.
headaches, migraines and epilepsy). There was also a final open
box for participants to share anything else that they feltwas relevant
to theirexperiencewith synaesthesia.Participantswhoreported that
their synaesthetic experiences resulted from a non-developmental
trigger (e.g. psychoactive drug use or epilepsy) were excluded.
Generation Scotland participants who consented to being
recontacted were invited to join the current study by email,
including a link to synaesthesia diagnostic tests hosted by the
University of Sussex. Demographic and relevant health infor-
mation was available through previous surveys conducted by
Generation Scotland.
BIG participants were asked a screening question about
whether or not they thought that they experienced synaesthesia,
as part of a larger survey. Those who replied that they did not
experience synaesthesia were eligible for the non-synaesthetic
control group. If the synaesthesia questionnaire information was
not available, participants were considered ‘synaesthesia status
unknown’ controls (table 2).
In the MPI cohort and Generation Scotland participants who
replied positively to a screening question about synaesthesia, gra-
pheme–colour synaesthesia was assessed through a commonly
used and validated online diagnostic test (known as the ‘test of con-
sistency’; see below) [33,34]. Letters (A–Z) and numbers (0–9) are
randomized and presented to the participant along with a colour
palette. Participants must choose the colour they feel most closely
matches their synaesthetic association, and each grapheme is pre-
sented three times during the test. The test is scored by calculating
the distance in colour space between the three colours chosen,
with smaller distances reflecting more similar colour choices. For
example, similar shades of red would generate a low score, while
a combination of pale pink, bright red and deep purple would pro-
duce a higher score. Lower scores thus indicate greater consistency
in colour selection, a known diagnostic feature of synaesthesia [35].
If a non-native English-speaker completed the grapheme–colour
consistency test through The Synesthesia Battery, they had the
option of using a non-Roman alphabet (e.g. Cyrillic or Hebrew).
Participants whose consistency test scores were collected by
the MPI were considered synaesthetic if they scored below 1.5
on the consistency test, and if at least 15 graphemes were
linked to colour sensations (thus only having synaesthetic experi-
ences for numbers 0–9 would be insufficient). Participants for
whom synaesthesia status was confirmed as part of prior studies
at the University of Sussex and the University of Edinburgh qua-
lified for this genetics study with a grapheme–colour consistency
score of 1.43 or less (following [36]). Participants from the Groot
Nationaal Onderzoek were invited to the genetics portion of the
study if they scored below 1.35 on the consistency test. University
of Amsterdam participants needed to pass the grapheme–colour
test within The Synesthesia Battery with a score of 1.0 or lower.
Within Generation Scotland, any individuals who reported
themselves as synaesthetic but failed the consistency test (scoring
above 1.5) were excluded from both the synaesthesia cases and
control group.
The number of types of synaesthesia a participant experi-
enced was calculated for all participants where we had access
to a complete survey of synaesthesia types. Following the cat-
egories described by Novich et al. [37], synaesthesia forms were
grouped into five clusters [37]. Self-report of one or more forms
of synaesthesia within a category added that category to an indi-
vidual’s score, for a maximum score of five (experiencing at least
one form of synaesthesia from each category).
Table 1. Participants with European ancestry in SynGenes, top 10 countries
of origin.
country number of participants
UK 199
The Netherlands 179
USA 117
Germany 38
Canada 29
Australia 23
Russia 19
royalsocietypublishing.org/journal/rstb
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4(c) DNA sampling
Participantswhomet the criteria for grapheme–colour synaesthesia
(see above for site-specific thresholds) were invited to join the gen-
etics portion of the study. At the MPI, mailing addresses were
requested via email. Those who replied with their address were
sent an Oragene DNA OG-500 saliva collection kit, along with
the participant information sheet, an ancestry survey and informed
consent documents. At theUniversity of Edinburgh, saliva samples
were collected onsite using the same Oragene kits. All saliva kits
were processed at the MPI according to the manufacturer’s instruc-
tions. Kits that yielded an insufficient amount of DNA for
genotyping were excluded from further analysis.
BIG participants contributed saliva samples using Oragene
kits as part of initial recruitment [30]. In the Generation Scotland
project, DNAwas isolated fromblood as previously described [27].Switzerland 12
Belgium 9
Italy 8
other 90
Table 2. Participant demographics.
cohort N
syna/non-
syn/unknown
n female
(%)
n Dutch
(%)
SynGenes 723 723/0/0 621 (86) 191 (26)
Generation
Scotland
1612 4/399/1209 1399 (87) 0 (0)
BIG 573 0/214/359 480 (84) 573 (100)
total 2908 727/613/1568 2500 (86) 764 (26)
aSynaesthetic.
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A total of 768 DNA samples processed at the MPI were genotyped
in two batches using the Illumina Human OmniExpressExome
genotyping array. Initial quality control steps were performed
using Illumina GenomeStudio software (v.2.0), following the pro-
tocol by Guo et al. [38], including clustering, removing all samples
with genotyping rates less than 98% and any SNPs that were miss-
ing inmore than 5% of samples (two sampleswere removed at this
step) [38]. The resulting genotypes were exported in PLINK bfile
format, and the remaining pre-imputation quality control steps
were performed using PLINK v.1.9 and 2.0. At the SNP-level,
the data were further filtered by removing SNPs that were out of
Hardy–Weinberg equilibrium (pHWE< 1 × 10−5).
At the subject-level, samples were checked for sex-mismatches
(a potential indicator of a sample processing error; none were
found). The process for recruiting synaesthetes did not exclude
family members from participating as long as they passed the con-
sistency test, and so a small number of synaesthetic parents and
siblings were genotyped. As close relatives would artificially skew
the case–control comparisons owing to their genetic similarity,
one individual from each pair of relatives was removed. This was
done by computing the proportion of identity-by-descent (pi-hat)
for every pair of participants, and removing one individual from
each pair where the pi-hat value was greater than 0.185 [39]. This
threshold identifies relatives between second and third degree,
and a total of 19 samples were removed at this step. Finally, as the
current study is focused on participants with European ancestry,
EIGENSTRAT v.6.1.4 was used (following the protocol outlined in
[38]) to identifyand removenon-European individuals viaprincipal
component analysis (PCA), leading to the removal of 23 samples.
The two genotyping batches were combined prior to imputa-
tion, and the PLINK .bim files were checked against the Human
Reference Consortium (HRC) reference SNP list using scripts
provided by William Rayner (https://www.well.ox.ac.uk/
~wrayner/tools/, v.4.2.9) [40].
DNA samples from the BIG cohort were genotyped in three
batches, using the Affymetrix 6.0, Illumina OmniExpress and
Psychiatric Genetics Consortium PsychChip arrays [32]. Pre-
imputation quality control was performed in PLINK as above,
and the batches were processed separately. Generation Scotland
genotype data were previously cleaned for missingness, and
close relatives (12 396 out of 20 032 original subjects) were
removed using PLINK 1.9 as above. Both the BIG and Generation
Scotland genotype data were checked for alignment with the
HRC reference list prior to imputation.(e) Imputation and final quality control
To ensure the maximum number of overlapping SNPs between
cohorts, each set of genotyping data was imputed using the
Michigan Imputation Server using the HRC r1.1 (2016) (seehttps://imputationserver.sph.umich.edu/start.html#!pages/hrc-
r1.1) imputation panel and SHAPEIT v2.r790 [41] for phasing [42].
Poorly imputed SNPs (R2 < 0.8) were removed and post-imputa-
tion quality control filters (SNP or sample missingness greater
than 10% and/or pHWE < 1 × 10−6) were applied to each cohort
separately. The cohorts were merged, removing any SNPs that
were multi-allelic or missing in one or more cohorts, resulting in
a final set of well-imputed SNPs that were present in all cohorts.
The combined dataset was given a final check for closely related
individuals to guard against the possibility that a participant
from the SynGenes cohort had a close relative who participated
in Generation Scotland or BIG—none were found.
( f ) Control matching
The combined imputed genotype data (excluding regions with
high linkage disequilibrium, e.g. the major histocompatibility com-
plex region) were pruned for linkage disequilibrium and 20
principal components (ancestry PCs)were calculated using PLINK.
In order to choose non-synaesthete control samples that were
as closely matched to the SynGenes cohort as possible, we first
removed clear outlying samples from that cohort based on the
first two ancestry PCs. One additional synaesthete sample was
inadvertently dropped from the analysis at this point, bringing
the final total to 723 SynGenes samples. Control samples from
BIG and Generation Scotland were prioritized by initially includ-
ing all known non-synaesthetes (replied ‘no’ to screening
questions), followed by balancing the male/female, Dutch/non-
Dutch ratios with ‘population controls’ for whom synaesthesia
status was unknown (table 2). Within each subgroup (e.g. non-
Dutch females), controls were randomly sampled so that the
total number of controls was three times the number of cases
royalsocietypublishing.org/journal/rstb
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5(oversampling for extra rigour). The ancestry PCs were recalcu-
lated using the final set of synaesthesia cases and controls, for
use as covariates in the polygenic score calculations.
(g) Polygenic score calculation
GWAS summary statistics for ASD and schizophrenia were
downloaded from the PGC (https://www.med.unc.edu/pgc/
results-and-downloads). The ASD data come from the combined
iPSYCH-PGC GWAS originally conducted in 2017 (18 381 ASD
cases) and the schizophrenia dataset is from their 2018 combined
study of schizophrenia and bipolar disorder (33 426 schizo-
phrenia cases) [24,43]. Summary statistics for BMI are based on
the UK Biobank sample of 361194 men and women, and were
downloaded from Benjamin Neale’s laboratory (http://www.
nealelab.is/uk-biobank). The GWAS effect measurements (odds
ratios, betas) were aligned to the risk (schizophrenia, ASD) or
trait (BMI) increasing alleles prior to calculating polygenic scores.
Polygenic scores for ASD, schizophrenia and BMI were
calculated using the PRSice software package [13]. Following
best practices for polygenic scoring, we included sex and 20
ancestry principal components as covariates [14]. Grapheme–
colour synaesthesia was treated as a binary target phenotype
with a prevalence of 0.014 [1]. The PRSice calculations excluded
the major histocompatibility complex region and included run-
ning 10 000 permutations of the best-fitting model in order to
generate an empirical p-value for the association between the
GWAS trait and synaesthesia that is controlled for Type 1 error.3. Results
(a) Generating a case–control sample for genetic
studies of grapheme–colour synaesthesia
As synaesthetic experiences had not been surveyed in any large
cohorts with existing genotype data, we first needed to recruit
and collect DNA samples from a large number of participants
with this condition. Synaesthesia takes a range of different
forms, and it isnot yetknownwhether similar genetic underpin-
nings are shared across them. Thus, to minimize heterogeneity
for these first studies, we ascertained our participants based
on one particular form of synaesthesia: grapheme–colour
synaesthesia. Our choice was based on several pragmatic fac-
tors: (i) the availability of well-validated consistency tests that
are reliable and can be completed online; (ii) its relatively high
population prevalence (1.4%); and (iii) the fact that this form
of synaesthesia is one of the more extensively studied in the
prior literature, albeit not yet at the genetic level.All participants
completed standard diagnostic (consistency) tests and met
the recruitment site-specific threshold for grapheme–colour
synaesthesia (scores below 1.5–1.0, see §2).
To complement this newly developed ‘SynGenes’ cohort,
we also surveyed two existing cohorts about synaesthetic
experiences. Generation Scotland participants who indicated
that they experienced grapheme–colour synaesthesia were
given the same consistency test as those in the SynGenes
cohort. Although the total number of verified synaesthetes
was low (n = 4), the survey also generated a pool of participants
who almost certainly do not experience synaesthesia. As 25%
of the final SynGenes cohort identified as Dutch (table 1), we
also included control participants taken from the Nijmegen
‘Brain Imaging Genetics’ (BIG) cohort (see §2).
Polygenic scores are known to be sensitive to subtle popu-
lation stratification [15] and we took several steps to match the
synaesthesia cases and controls on ancestry. We used PCA torepresent subjects’ genotype data as 20 components that cap-
ture increasingly small fractions of the genetic differences
among the subjects in the analysis. This technique can clearly
separate individuals from different population backgrounds
(figure 1c) and is frequently used as both a quality control
step to remove obvious outliers and as a source of covariates
to control for potentially confounding ancestry differences in
GWAS and other population genetics methods.
Twenty-three subjects were removed from the SynGenes
cohort owing to non-European ancestry based on PCA (see
§2). We then used a further round of PCA with the combined
set of SynGenes, BIG and Generation Scotland to remove sig-
nificant outliers along the first two components (22 subjects
removed, figure 1). Following genotype quality control (see
§2) and this further PCA step, the final set of synaesthetes (Syn-
Genes plus four synaesthetes from Generation Scotland)
numbered 727 (table 2).
The control samples were selected by first including all
remaining subjects who were known to be non-synaesthetic,
followed by randomly sampling from the Generation Scotland
and BIG subjects whose synaesthesia status was unknown,
ensuring that the female : male and Dutch : non-Dutch ratios
matched the synaesthesia cases (table 2).
(b) Assessing polygenic scores across synaesthetes
and controls
In order to begin placing synaesthesia in the context of other
brain-related traits with well-studied genetic bases, we chose
to assess differences in polygenic scores between synaesthetes
and controls. We focused the PGS analysis on two neuropsy-
chiatric conditions previously linked to synaesthesia at the
phenotypic level—schizophrenia and ASD. Levels of positive
and disorganized schizotypy were higher in individuals who
experienced synaesthetic associations with colour in a 2012
study by Banissy et al. [19]. The positive schizotypy finding
was later replicated and found to be unrelated to synaesthetes’
elevated capacity for visual imagery [44]. Multiple studies
have demonstrated relationships between aspects of ASD
and synaesthesia, including increased sensory sensitivity in
synaesthetes and an increased prevalence of synaesthesia
among people with ASD who also have savant skills [20–22].
Briefly, the analysis involved using logistic regression to
predict synaesthesia status based on the PGS, with sex and
20 ancestry principal components included as covariates.
For each trait (schizophrenia, ASD and BMI), we took the
prior published GWAS data summary statistics and used
that information to construct a PGS. Consistent with standard
procedures, we varied the p-value threshold that we used for
determining which SNPs from the GWAS should be included
in the PGS, and compared its performance in the model.
A stricter threshold means that the PGS is constructed with
fewer SNPs and accounts for a smaller degree of variance
in the trait tested in the GWAS. Lowering the threshold, to
be more permissive in how many SNPs are included, has
the potential to include more SNPs that contribute to the var-
iance in the GWAS trait (figure 2c). The best-fitting PGS was
the one that made the greatest improvement to the model’s
power to accurately predict synaesthesia status.
Using GWAS summary statistics from the Psychiatric
Genetics Consortium’s (PGC) most recent published study
of schizophrenia and bipolar disorder (33 426 schizophrenia
cases, mainly of European ancestry), we calculated
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Figure 1. Final principal components (PCs) reflecting genetic variation owing to ancestry differences after matching synaesthetes and controls on self-reported ancestry.
(a) The first two PCs for genetic ancestry, with colours indicating contributing cohorts (BIG = controls only; Generation Scotland = mainly controls; SynGenes = cases
only). (b) The same PCs split by case/control status. (c) PCs 1–4 from a separate PCA that includes samples from the four major populations studied in the 1000 Genomes
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royalsocietypublishing.org/journal/rstb
Phil.Trans.R.Soc.B
374:20190026
6schizophrenia PGSs using multiple p-value thresholds [43].
The best-fitting model, assessing evidence for an association
between schizophrenia PGS and synaesthesia, was identified
for alleles selected at a p-value threshold of 0.0003, and
included 1925 SNPs from the base schizophrenia GWAS
(figure 2c, blue line). At this threshold, the PGS accounted
for 0.47% of the variance in synaesthesia status (Nagelkerke’s
R2 = 0.0047, adjusted for ascertainment), an association that
remained statistically significant after 10 000 permutations
(unadjusted p = 0.00015, empirical p = 0.0027) (figure 2a).
As selecting a p-value threshold based on its ability to
predict synaesthesia status generates an R2 value that is necess-
arily overfitted, we also assessed the relationship between
synaesthesia status and the schizophrenia PGS using weighted
information from all available SNPs across the genome. A pre-
vious meta-analysis of schizophrenia GWAS by the PGC used
this unconstrained approach to determine howmuch of the var-
iance in schizophrenia diagnosis can be explained by
cumulative genetic risk for schizophrenia [43]. Other studies
testing associations of schizophrenia PGSs with different traits
have tested a range of p-value thresholds and reported the
one that best predicted the target trait (as above), leading to
adoption of a wide variety of p-value thresholds across the
literature [45]. We found that the unthresholded schizophrenia
PGS could account for 0.27% of the variance in synaesthesia
status in our cohort (Nagelkerke’s R2 = 0.0027, adjusted
for ascertainment), a statistically significant association
(unadjusted p = 0.0039, empirical p = 0.0041).
To better understand how a schizophrenia PGS is
associated with the odds of experiencing grapheme–coloursynaesthesia, we split the combined set of cases and controls
into 20 quantiles based on the best-fitting PGS. We observed
a trend for increasing odds of having synaesthesiawith increas-
ing schizophrenia (SCZ) PGS load, although the 95%
confidence intervals around the odds-ratios were wide and
included 1.0 for both the lowest and highest quantiles of
schizophrenia PGS (figure 2b).
In an exploratory follow-up analysis, we investigated
potential relationships between additional aspects of synaes-
thetic experiences and schizophrenia PGS. A full survey of
synaesthetic forms was available for 292 individuals. The
number of forms of synaesthesia each person reported
was scored as in Novich et al. [37], where related forms are
combined and the maximum possible score is five [37]. The
total number of forms of synaesthesia that a person experienced
was not significantly correlated with their schizophrenia
PGS (Spearman’s Rho = 0.012, p = 0.84, average number of
types = 2.55, s.d. = 1.07). The most common forms (following
the Novich descriptions) were, in order, coloured sequence
synaesthesia (n = 292), sequence–space synaesthesia (n = 145),
coloured sensation (n = 138), coloured music (n = 123) and
non-visual sequalae synaesthesia (n = 47). A total of 217 partici-
pants also completed the Projector-Associator survey as part
of the Synesthesia Battery [46]. The survey asks whether synaes-
thetic experiences are perceived ‘in themind’s eye’ (associators)
or externally (projectors) [47,48]. This facet of synaesthetic
experience was also unrelated to the schizophrenia PGS
(two-sample t-test, t = 0.55, d.f. = 58, p = 0.59).
We used summary statistics from the PGC-iPSYCH
autism GWAS (18 381 ASD cases, European ancestry) to
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Figure 2. Relationship between schizophrenia polygenic scores and grapheme–colour synaesthesia. (a) Comparison of PGS model fit across several p-value thresholds
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7construct PGSs for both synaesthetes and controls [24]. Using
the same covariates and synaesthesia prevalence as above, we
calculated autism PGSs across the same range of p-value
thresholds as before. We found that the best-fitting model
used a p-value threshold of 0.0001, including 285 SNPs
from the autism GWAS. In this case, even this best-fitting
model was unable to predict synaesthesia status based on
autism PGS (Nagelkerke’s R2 = 0.00092, p = 0.091, empirical
p = 0.54), indicating that polygenic risk for ASD, at least
from the currently available GWAS data, cannot distinguish
synaesthetes from non-synaesthetes (figure 2a).
In order to determine if the subtle effects we saw for
schizophrenia PGSs were owing to non-specific genetic
differences between the synaesthetes and non-synaesthetes
(e.g. owing to remaining differences in ancestry), we calcu-
lated PGSs for BMI using summary statistics available from
the UK Biobank. BMI is an ideal negative control as we do
not a priori expect genetic risk for high BMI to have any
relationship with synaesthesia status, and the GWAS for
this unrelated trait involved a very large sample of European
ancestry (n = 336 107). The PGS for BMI performed the worst
of the three traits examined. The best-fitting model, based on
a p-value threshold of 0.0027, including 30 454 SNPs from the
BMI GWAS, failed to predict synaesthesia (R2 = 0.00058, p =
0.18, empirical p = 0.60) (figure 2a). These results suggest
that the cases and controls are well-matched, as uncorrected
population stratification between the samples would beexpected to introduce differences in non-psychiatric traits
that also have a genetic basis.4. Discussion
In this study, we present a new cohort of over 700 unrelated
individuals with verified grapheme–colour synaesthesia and
genotype data, and provide the first analyses of genetic
relationships between synaesthesia and other brain-related
traits, based on common polymorphisms.
We found that there was a significant relationship between
aggregate genetic risk for schizophrenia and synaesthesia.
However, the amount of variance explained was extremely
small and synaesthetes were indistinguishable from non-
synaesthetes at either the highest or lowest quantiles of schizo-
phrenia PGS. We did not see significant effects with PGSs for
risk of autism, another brain-related trait that has been hypoth-
esized to have connections to synaesthesia based on prior
work. Nor did we see any genetic relationship with higher
BMI, used here as a negative control. In investigation of a
subset of the sample with available data, we did not find
a relationship between schizophrenia PGSs and how many
types of synaesthesia participants reported. Nor did we see
an association with associator–projector status, i.e. whether
participants experience the secondary percept in the mind’s
eye or externally.
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8Synaesthesia is a perceptual phenomenon that can occur in
otherwise neurotypical individuals, although being neurotypi-
cal is not a diagnostic criterion. It has been argued that
experiencing synaesthesia should be considered an all-or-
nothing designation rather than the tail end of a distribution
that extends into cross-modal correspondences in the general
population [49]. Other studies describing the psychological
and/or neuropsychiatric profiles of synaesthetes using tools
designed to measure levels of disorder-related traits in healthy
populations (e.g. the Autism-SpectrumQuotient or the Oxford-
Liverpool Inventory of Feelings and Experiences, O-LIFE) have
shown that synaesthetes are only subtly different from non-
synaesthetes on these other dimensions [19,20,44,50]. Informed
by these results, we framed synaesthesia in this study as a
binary trait that may have modest quantitative relationships
with aspects of other neurological traits at the genetic level.
We examined the potential for such a relationship bet-
ween synaesthesia and schizophrenia based on reports that
synaesthetes experience higher levels of positive schizotypy
compared to controls [19,44]. Specifically, in two separate
studies, synaesthetes scored higher on the Unusual Experiences
subscale of the O-LIFE, which measures positive schizotypy
through questions on perceptual aberrations, hallucinations
and magical thinking. In prior work connecting schizotypy in
the general population to schizophrenia, levels of positive and
negative schizotypy were positively correlated with schizo-
phrenia PGS in healthy controls as well as healthy relatives of
individuals with schizophrenia [23]. Our analyses of schizo-
phrenia PGSs in the present study demonstrate an extremely
subtle, but measurable, relationship between genetic risk for
schizophrenia and grapheme–colour synaesthesia (figure 2a,b).
This result should be considered from two angles: its relevance
as a predictor of grapheme–colour synaesthesia, and what it
reveals about the genetic basis of a perception-related trait-like
synaesthesia. Although not robust enough to distinguish
synaesthetes from non-synaesthetes even at the extreme ends
of the distribution (figure 2b), we speculate that research into
the genetic overlap between these traits may reveal firmer
connections as the sample of synaesthetes increases.
Just as for other neuropsychiatric traits, the role of common
genetic variation in schizophrenia is highly complex, with
GWAS efforts identifying a large number of genome-wide sig-
nificant risk alleles andmanymore loci that still contribute to its
heritability [43,51] (figure 2c). Schizophrenia shows positive
genetic correlations with bipolar disorder andmajor depressive
disorder (and weakly with ASD) such that increased risk for
one condition increases the risk for the others owing to
shared genetic factors. Using the PGS approach instead of gen-
etic correlation methods, schizophrenia PGSs can explain
around 6% of the variation in bipolar disorder and major
depressive disorder [45]. We wish to emphasize that not all of
the shared biology points toward disorder—schizophrenia
risk is also genetically correlated with increased educational
attainment, a trait strongly linked to higher cognitive perform-
ance [52–54]. A recent systematic review of the schizophrenia
PGS literature notes that these scores have much lower associ-
ation with cognitive traits, explaining a maximum of 0.7% of
the variance [45]. Previous work also showed a genetic link
between schizophrenia and creativity, with schizophrenia
PGSs explaining 0.24% of the variance in whether someone
was amember of a professional society related to a creative pur-
suit (e.g. visual arts, writing and acting) [25]. Interestingly,
alongside the differences in disorder-related traits, synaesthetesshow enhanced performance on a variety of learning and
memory tasks, and are more likely to be involved in creative
pursuits [55–57]. It is important to emphasize that common
genetic variation (i.e. polymorphisms that are observed at
appreciable frequency in the population) only captures a por-
tion of what makes these traits heritable, and that this limits
the scope of genetic correlations between traits that are derived
from SNP data. A long-term goal of such research is to under-
stand how these traits form an interconnected web of shared
biology, and the current study offers just a first impression of
how synaesthesia may fit into this framework.
Proposed relationships between synaesthesia and ASD are
nuanced, but the clearest suggested link between them is likely
altered sensory sensitivity [20,58]. While the prevalence of
synaesthesia among peoplewith ASD varies by study, it is con-
sistently elevated and likely highest for individualswith savant
abilities [21,22,59]. Unfortunately, there are no published inves-
tigations of genomic associations with sensory sensitivity, and
sample sizes for GWAS studies of ASD lag far behind those of
schizophrenia and other neuropsychiatric traits, with only a
handful of genome-wide significant loci identified so far [24].
By contrast, rare mutations in hundreds of different genes
have been linked to ASD, and such rare genetic variation is
thought to be a major contributor to the condition [60]. It is
possible that common genetic variation plays a smaller role
in ASD than schizophrenia, and that even with a more power-
ful GWAS the number of significant loci would remain low
[61]. This would limit the utility of PGS-based methods for
linking ASD to traits like synaesthesia and elevate study
designs that instead compare the downstreambiological conse-
quences of rare genetic variation across traits. In a previous
study, we identified rare genetic variants in three families
with sound–colour synaesthesia, but found little overlap with
known genes that have been implicated in ASD risk [9]. Path-
way-based approaches focusing on genes rather than specific
variants within genes may prove more effective at deciphering
the biology underlying the shared sensory sensitivity and
increased prevalence of synaesthetic experiences among
people with ASD [20–22].
The limitations facing the current study stem from sample
size, both for the synaesthesia cohort and the available
GWAS data used in the PGS calculations. As the largest ASD
GWAS includes roughly half as many cases as the most
recent schizophrenia meta-analysis, we expected a less infor-
mation-rich dataset with which to construct the PGSs. We
calculated PGSs for a range of p-value thresholds to identify
the best-fitting model; however, the relative lack of strong
effect sizes in the ASD GWAS led to a model based on only
285 SNPs compared to 1925 in the schizophrenia PGS. Applica-
bility across populations is a general limitation of PGS—
current best practices warn against applying a PGS built
using genetic data from Europeans to non-European popu-
lations. We worked to reduce the impact of population
stratification on our results by matching the synaesthetes and
controls on self-reported ancestry and including 20 principal
components as covariates in the PGS calculations (tables 1
and 2 and figure 1). As the BMI GWAS in UK Biobank is
10-times larger than the schizophrenia sample, the lack of
difference in BMI PGSs between synaesthesia cases and con-
trols in the present study suggests that our groups were
generally well-matched. Finally, we were limited here to a
PGS approach because we are underpowered to more directly
detect genetic correlations between synaesthesia and other
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9traits, as we are currently unable to accurately measure how
much of the heritability of synaesthesia is accounted for by
common genetic variation. In studying SNP-based genetic cor-
relations between two traits the heritability accounted for by
common variation (called ‘SNP-heritability’, to distinguish it
from heritability measures based on twin-studies) must be
known for both traits. We expect that future studies, with
increased sample sizes for both synaesthesia and ASD cohorts,
will overcome these hurdles and offer a better understanding
of how the traits are connected.
In sum, this study introduces a new cohort of consistency
test-verified synaesthetes, with accompanying genotype infor-
mation across the genome, and offers the first genetic threads
linking this unusual phenomenon to better understood brain-
related traits. Large-scale GWAS efforts, like those available
for educational attainment and schizophrenia, have already
uncovered a network of interrelated traitswith varying degrees
of genetic overlap.While easy-to-survey measures like years of
education or neuropsychiatric diagnoses are assessed for ever
larger and more powerful genotyped cohorts, traits related to
perception lag behind. There is still much to learn about how
synaesthesia, as amodel of natural variation in sensory percep-
tion, is connected to this larger network. Such efforts may
reveal how genetic variation ripples through interconnected
neurological traits, not only boosting or suppressing risk for
disorder, but fine-tuning the neural substrates on which
perception is built.
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